{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,6]],"date-time":"2025-07-06T13:40:06Z","timestamp":1751809206812,"version":"3.41.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,6]],"date-time":"2025-07-06T00:00:00Z","timestamp":1751760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,6]],"date-time":"2025-07-06T00:00:00Z","timestamp":1751760000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP18K15566","JP22K15852","JP20K08061"],"award-info":[{"award-number":["JP18K15566","JP22K15852","JP20K08061"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["A134"],"award-info":[{"award-number":["A134"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EJNMMI radiopharm. chem."],"DOI":"10.1186\/s41181-025-00361-8","type":"journal-article","created":{"date-parts":[[2025,7,6]],"date-time":"2025-07-06T13:04:15Z","timestamp":1751807055000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Development of a CYP11B2 imaging tracer for primary aldosteronism: basic evaluation of iodine- and fluorine-incorporated pyridinyldihydroquinolinone derivatives"],"prefix":"10.1186","volume":"10","author":[{"given":"Yusuke","family":"Yagi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4291-3524","authenticated-orcid":false,"given":"Hiroyuki","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riko","family":"Fuseda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takaaki","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"Omokawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaito","family":"Ohta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoko","family":"Kise","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masakatsu","family":"Sone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Yasui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuya","family":"Inagaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideo","family":"Saji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,6]]},"reference":[{"key":"361_CR1","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1210\/jc.2015-3431","volume":"101","author":"T Abe","year":"2016","unstructured":"Abe T, Naruse M, Young WF Jr, Kobashi N, Doi Y, Izawa A, et al. A novel CYP11B2-specific imaging agent for detection of unilateral subtypes of primary aldosteronism. J Clin Endocrinol Metab. 2016;101:1008\u201315. https:\/\/doi.org\/10.1210\/jc.2015-3431. (PMID: 26756116).","journal-title":"J Clin Endocrinol Metab."},{"key":"361_CR2","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1161\/HYPERTENSIONAHA.116.07716","volume":"69","author":"K Bogman","year":"2017","unstructured":"Bogman K, Schwab D, Delporte ML, Palermo G, Amrein K, Mohr S, et al. Preclinical and early clinical profile of a highly selective and potent oral inhibitor of aldosterone synthase (CYP11B2). Hypertension. 2017;69:189\u201396. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.116.07716. (PMID: 27872236).","journal-title":"Hypertension"},{"key":"361_CR3","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1210\/jc.2011-1537","volume":"97","author":"TJ Burton","year":"2012","unstructured":"Burton TJ, Mackenzie IS, Balan K, Koo B, Bird N, Soloviev DV, et al. Evaluation of the sensitivity and specificity of (11)C-metomidate positron emission tomography (PET)-CT for lateralizing aldosterone secretion by Conn\u2019s adenomas. J Clin Endocrinol Metab. 2012;97:100\u20139. https:\/\/doi.org\/10.1210\/jc.2011-1537.","journal-title":"J Clin Endocrinol Metab"},{"key":"361_CR4","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1097\/00008571-199504000-00005","volume":"5","author":"K Denner","year":"1995","unstructured":"Denner K, Vogel R, Schmalix W, Doehmer J, Bernhardt R. Cloning and stable expression of the human mitochondrial cytochrome P45011B1 cDNA in V79 Chinese hamster cells and their application for testing of potential inhibitors. Pharmacogenetics. 1995;5:89\u201396. https:\/\/doi.org\/10.1097\/00008571-199504000-00005. (PMID: 7663533).","journal-title":"Pharmacogenetics"},{"key":"361_CR5","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1161\/HYPERTENSIONAHA.121.18761","volume":"79","author":"JW Funder","year":"2022","unstructured":"Funder JW, Carey RM. Primary aldosteronism: where are we now? Where to From Here? Hypertension. 2022;79:726\u201335. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.121.18761. (PMID: 35067069).","journal-title":"Hypertension"},{"key":"361_CR6","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.mce.2013.11.022","volume":"383","author":"CE Gomez-Sanchez","year":"2014","unstructured":"Gomez-Sanchez CE, Qi X, Velarde-Miranda C, Plonczynski MW, Parker CR, Rainey W, et al. Development of monoclonal antibodies against human CYP11B1 and CYP11B2. Mol Cell Endocrinol. 2014;383:111\u20137. https:\/\/doi.org\/10.1016\/j.mce.2013.11.022. (PMID: 24325867).","journal-title":"Mol Cell Endocrinol"},{"key":"361_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2024.116521","volume":"274","author":"C Guo","year":"2024","unstructured":"Guo C, Zhang G, Wu C, Lei Y, Wang Y, Yang J. Emerging trends in small molecule inhibitors targeting aldosterone synthase: a new paradigm in cardiovascular disease treatment. Eur J Med Chem. 2024;274: 116521. https:\/\/doi.org\/10.1016\/j.ejmech.2024.116521. (PMID: 38820853).","journal-title":"Eur J Med Chem"},{"key":"361_CR8","doi-asserted-by":"publisher","first-page":"2358","DOI":"10.1210\/jc.2008-0050","volume":"93","author":"S Hahner","year":"2008","unstructured":"Hahner S, Stuermer A, Kreissl M, Reiners C, Fassnacht M, Haenscheid H, et al. [123 I]Iodometomidate for molecular imaging of adrenocortical cytochrome P450 family 11B enzymes. J Clin Endocrinol Metab. 2008;93:2358\u201365. https:\/\/doi.org\/10.1210\/jc.2008-0050. (PMID: 18397978).","journal-title":"J Clin Endocrinol Metab"},{"key":"361_CR9","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1210\/jc.2012-3045","volume":"98","author":"S Hahner","year":"2013","unstructured":"Hahner S, Kreissl MC, Fassnacht M, Haenscheid H, Bock S, Verburg FA, et al. Functional characterization of adrenal lesions using [123I]IMTO-SPECT\/CT. J Clin Endocrinol Metab. 2013;98:1508\u201318. https:\/\/doi.org\/10.1210\/jc.2012-3045.","journal-title":"J Clin Endocrinol Metab"},{"key":"361_CR10","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1007\/s00423-010-0681-7","volume":"395","author":"J Hennings","year":"2010","unstructured":"Hennings J, Sundin A, H\u00e4gg A, Hellman P. 11C-metomidate positron emission tomography after dexamethasone suppression for detection of small adrenocortical adenomas in primary aldosteronism. Langenbecks Arch Surg. 2010;395:963\u20137. https:\/\/doi.org\/10.1007\/s00423-010-0681-7.","journal-title":"Langenbecks Arch Surg"},{"key":"361_CR11","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/jhh.2016.61","volume":"31","author":"K Kamemura","year":"2017","unstructured":"Kamemura K, Wada N, Ichijo T, Matsuda Y, Fujii Y, Kai T, et al. Significance of adrenal computed tomography in predicting laterality and indicating adrenal vein sampling in primary aldosteronism. J Hum Hypertens. 2017;31:195\u20139. https:\/\/doi.org\/10.1038\/jhh.2016.61. (PMID: 27582025).","journal-title":"J Hum Hypertens"},{"key":"361_CR12","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1111\/eci.12746","volume":"47","author":"R Ladurner","year":"2017","unstructured":"Ladurner R, Sommerey S, Buechner S, Dietz A, Degenhart C, Hallfeldt K, et al. Accuracy of adrenal imaging and adrenal venous sampling in diagnosing unilateral primary aldosteronism. Eur J Clin Invest. 2017;47:372\u20137. https:\/\/doi.org\/10.1111\/eci.12746. (PMID: 28299775).","journal-title":"Eur J Clin Invest"},{"key":"361_CR13","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1021\/jm101470k","volume":"54","author":"S Lucas","year":"2011","unstructured":"Lucas S, Negri M, Heim R, Zimmer C, Hartmann RW. Fine-tuning the selectivity of aldosterone synthase inhibitors: Structure\u2212activity and structure\u2212selectivity insights from studies of heteroaryl substituted 1,2,5,6-Tetrahydropyrrolo[3,2,1-ij]quinolin-4-one derivatives. J Med Chem. 2011;54:2307\u201319. https:\/\/doi.org\/10.1021\/jm101470k.","journal-title":"J Med Chem"},{"key":"361_CR14","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.mce.2016.10.014","volume":"441","author":"K Nishimoto","year":"2017","unstructured":"Nishimoto K, Koga M, Seki T, Oki K, Gomez-Sanchez EP, Gomez-Sanchez CE, et al. Immunohistochemistry of aldosterone synthase leads the way to the pathogenesis of primary aldosteronism. Mol Cell Endocrinol. 2017;441:124\u201333. https:\/\/doi.org\/10.1016\/j.mce.2016.10.014. (PMID: 27751767).","journal-title":"Mol Cell Endocrinol"},{"key":"361_CR15","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1016\/S2213-8587(21)00210-2","volume":"9","author":"M Reincke","year":"2021","unstructured":"Reincke M, Bancos I, Mulatero P, Scholl UI, Stowasser M, Williams TA. Diagnosis and treatment of primary aldosteronism. Lancet Diabetes Endocrinol. 2021;9:876\u201392. https:\/\/doi.org\/10.1016\/S2213-8587(21)00210-2. (PMID: 34798068).","journal-title":"Lancet Diabetes Endocrinol"},{"key":"361_CR16","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s12149-023-01851-y","volume":"37","author":"X Ren","year":"2023","unstructured":"Ren X, Cheng G, Wang Z. Advances in the molecular imaging of primary aldosteronism. Ann Nucl Med. 2023;37:433\u201341. https:\/\/doi.org\/10.1007\/s12149-023-01851-y. (PMID: 37393373).","journal-title":"Ann Nucl Med"},{"key":"361_CR17","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.1016\/j.jacc.2019.09.057","volume":"74","author":"GP Rossi","year":"2019","unstructured":"Rossi GP. Primary aldosteronism: JACC state-of-the-art review. J Am Coll Cardiol. 2019;74:2799\u2013811. https:\/\/doi.org\/10.1016\/j.jacc.2019.09.057. (PMID: 31779795).","journal-title":"J Am Coll Cardiol"},{"key":"361_CR18","doi-asserted-by":"publisher","first-page":"9321","DOI":"10.1021\/acs.jmedchem.1c00539","volume":"64","author":"K Sander","year":"2021","unstructured":"Sander K, Gendron T, Cybulska KA, Sirindil F, Zhou J, Kalber TL, et al. Development of [18F]AldoView as the first highly selective aldosterone synthase PET tracer for imaging of primary hyperaldosteronism. J Med Chem. 2021;64:9321\u20139. https:\/\/doi.org\/10.1021\/acs.jmedchem.1c00539.","journal-title":"J Med Chem"},{"key":"361_CR19","doi-asserted-by":"publisher","first-page":"6632","DOI":"10.1021\/jm0503704","volume":"48","author":"M Voets","year":"2005","unstructured":"Voets M, Antes I, Scherer C, M\u00fcller-Vieira U, Biemel K, Barassin C, et al. Heteroaryl-substituted naphthalenes and structurally modified derivatives: selective inhibitors of CYP11B2 for the treatment of congestive heart failure and myocardial fibrosis. J Med Chem. 2005;48:6632\u201342. https:\/\/doi.org\/10.1021\/jm0503704. (PMID: 16220979).","journal-title":"J Med Chem"},{"key":"361_CR20","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1161\/HYPERTENSIONAHA.110.168484","volume":"57","author":"O Vonend","year":"2011","unstructured":"Vonend O, Ockenfels N, Gao X, Allolio B, Lang K, Mai K, et al. Adrenal venous sampling: evaluation of the German Conn\u2019s registry. Hypertension. 2011;57:990\u20135. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.110.168484.","journal-title":"Hypertension"},{"key":"361_CR21","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1038\/s41591-022-02114-5","volume":"29","author":"X Wu","year":"2023","unstructured":"Wu X, Senanayake R, Goodchild E, Bashari WA, Salsbury J, Cabrera CP, et al. [11C]metomidate PET-CT versus adrenal vein sampling for diagnosing surgically curable primary aldosteronism: a prospective, within-patient trial. Nat Med. 2023;29:190\u2013202. https:\/\/doi.org\/10.1038\/s41591-022-02114-5. (PMID:36646800 PMCID: PMC9873572).","journal-title":"Nat Med"},{"key":"361_CR22","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1038\/s41440-023-01288-w","volume":"46","author":"Y Yoshida","year":"2023","unstructured":"Yoshida Y, Shibata H. Recent progress in the diagnosis and treatment of primary aldosteronism. Hypertens Res. 2023;46:1738\u201344. https:\/\/doi.org\/10.1038\/s41440-023-01288-w. (PMID: 37198444).","journal-title":"Hypertens Res"},{"key":"361_CR23","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1055\/a-2106-4663","volume":"131","author":"N Younes","year":"2023","unstructured":"Younes N, Larose S, Bourdeau I, Therasse E, Lacroix A. Role of adrenal vein sampling in guiding surgical decision in primary aldosteronism. Exp Clin Endocrinol Diabetes. 2023;131:418\u201334. https:\/\/doi.org\/10.1055\/a-2106-4663. (PMID: 37567230).","journal-title":"Exp Clin Endocrinol Diabetes"}],"container-title":["EJNMMI Radiopharmacy and Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41181-025-00361-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41181-025-00361-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41181-025-00361-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,6]],"date-time":"2025-07-06T13:04:15Z","timestamp":1751807055000},"score":1,"resource":{"primary":{"URL":"https:\/\/ejnmmipharmchem.springeropen.com\/articles\/10.1186\/s41181-025-00361-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,6]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["361"],"URL":"https:\/\/doi.org\/10.1186\/s41181-025-00361-8","relation":{},"ISSN":["2365-421X"],"issn-type":[{"value":"2365-421X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,6]]},"assertion":[{"value":"14 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal experiments were conducted according to Kyoto University and Kyoto Pharmaceutical University guidelines, and the study protocol was approved by the Institutional Experimental Animal Committee (Approval Number: 12\u201318, ABCH-19\u2013013). The study protocol of in vitro ARG using human adrenal sections was reviewed and approved by Kyoto University Graduate School and Faculty of Medicine and Kyoto Pharmaceutical University, Ethics Committee (Approval Number: G0672, 20\u201318-24).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All data generated or analyzed during this study are included in this published article and its supplementary information files.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"The authors declare no competing financial interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"39"}}